Key result
Ischemic stroke reperfusion from 2014 to 2021 linked to ~4% greater 90-day functional independence.
Why the study?
Acute ischaemic stroke treatment has seen major changes in reperfusion therapies over recent decades, prompting an analysis of temporal trends in reperfusion treatment, functional outcomes, and mortality.
Have rates of reperfusion treatment, functional outcomes, and mortality improved over time for first-ever ischaemic stroke patients in Norway?
Observational (n=45,686)
Yes
Have rates of reperfusion treatment, functional outcomes, and mortality improved over time for first-ever ischaemic stroke patients in Norway?
Absolute Event Rate: 68.1% vs 64.2%
Between 2014 and 2021 in Norway, the use of reperfusion therapies for acute ischemic stroke increased, accompanied by improved 90-day functional outcomes and reduced mortality.
Increasing reperfusion use in AIS may improve outcomes; leaves open whether trends reflect causation in registry data.
No takes yet. Share an insight, caveat, or question.
Elangwe et al. (2025) conducted an observational in First-ever acute ischaemic stroke (n=45,686). Time period (2014 to 2021) vs. 2014 baseline was evaluated on Functional outcome defined by modified Rankin Scale (mRS) score 0-2 at 90 days. From 2014 to 2021, the proportion of first-ever acute ischemic stroke patients achieving functional independence (mRS 0-2) at 90 days increased from 64.2% to 68.1%, and 90-day mortality decreased from 11.7% to 10.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: